Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cue Biopharma Inc
(NQ:
CUE
)
0.7695
-0.0456 (-5.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cue Biopharma Inc
< Previous
1
2
3
Next >
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
August 15, 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
May 30, 2024
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.
Via
InvestorPlace
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 02, 2024
Via
Benzinga
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
April 09, 2024
Via
Benzinga
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
April 02, 2024
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Where Cue Biopharma Stands With Analysts
June 15, 2023
Via
Benzinga
Cue Biopharma Earnings Perspective: Return On Capital Employed
March 22, 2023
Via
Benzinga
Cue Biopharma's Earnings Outlook
March 20, 2023
Via
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 01, 2024
Via
Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
December 14, 2023
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.
Via
InvestorPlace
The Truth About IPO Investing
September 02, 2023
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
August 30, 2023
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Biotech Stocks to Buy as Companies Ink Major Deals
June 22, 2023
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy.
Via
InvestorPlace
3 Biotech Stocks Sitting on Huge-Upside Catalysts
May 26, 2023
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks.
Via
InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
May 05, 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.
Via
InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
May 04, 2023
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.
Via
InvestorPlace
Earnings Scheduled For March 21, 2023
March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 24, 2022
Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning!
Via
InvestorPlace
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
October 24, 2022
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 01, 2022
Via
Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
August 22, 2022
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
June 28, 2022
On Tuesday, 87 companies hit new 52-week lows.
Via
Benzinga
Cue Biopharma's Return On Capital Employed Overview
June 14, 2022
Benzinga Pro data, Cue Biopharma (NASDAQ:CUE) reported Q1 sales of $1.00 million. Earnings fell to a loss of $14.26 million, resulting in a 70.02% decrease from last quarter.
Via
Benzinga
FDA Accepts IND for Cue Biopharma's CUE-102 in the treatment of Wilms' Tumor 1 (WT1)
May 11, 2022
Cue Biopharma, Inc. (NASDAQ: CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 06, 2022
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.